Symbols / OLMA $15.17 +0.73% Olema Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
OLMA Chart
About

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 1.32B
Enterprise Value 811.34M Income -162.45M Sales —
Book/sh 5.88 Cash/sh 5.80 Dividend Yield —
Payout 0.00% Employees 131 IPO —
P/E — Forward P/E -5.96 PEG —
P/S — P/B 2.58 P/C —
EV/EBITDA -4.82 EV/Sales — Quick Ratio 9.84
Current Ratio 9.95 Debt/Eq 0.88 LT Debt/Eq —
EPS (ttm) -1.87 EPS next Y -2.54 EPS Growth —
Revenue Growth — Earnings 2026-05-12 ROA -21.42%
ROE -36.61% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 87.16M
Shs Float 67.43M Short Float 10.18% Short Ratio 4.11
Short Interest — 52W High 36.26 52W Low 2.86
Beta 2.18 Avg Volume 1.69M Volume 870.23K
Target Price $43.00 Recom Strong_buy Prev Close $15.06
Price $15.17 Change 0.73%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$43.00
Mean price target
2. Current target
$15.17
Latest analyst target
3. DCF / Fair value
$-17.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.17
Low
$27.00
High
$62.00
Mean
$43.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-27 init Wolfe Research — → Peer Perform —
2026-03-18 main JP Morgan Overweight → Overweight $58
2026-03-18 main Goldman Sachs Buy → Buy $27
2026-03-17 main Citigroup Buy → Buy $62
2026-03-17 main Guggenheim Buy → Buy $38
2026-03-09 main HC Wainwright & Co. Buy → Buy $38
2026-02-11 init Stifel — → Buy $48
2026-01-07 init UBS — → Buy $45
2026-01-07 init Piper Sandler — → Overweight —
2025-12-12 main Citigroup Buy → Buy $60
2025-12-11 main Oppenheimer Outperform → Outperform $48
2025-12-11 main Goldman Sachs Buy → Buy $38
2025-12-11 main HC Wainwright & Co. Buy → Buy $45
2025-11-21 main Goldman Sachs Buy → Buy $26
2025-11-18 main Oppenheimer Outperform → Outperform $45
2025-11-18 main HC Wainwright & Co. Buy → Buy $36
2025-11-18 main JP Morgan Overweight → Overweight $32
2025-10-20 reit HC Wainwright & Co. Buy → Buy $28
2025-10-08 init Guggenheim — → Buy $20
2025-09-03 main Oppenheimer Outperform → Outperform $22
News
RSS: Latest OLMA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 MITCHELL SHAWNTE Officer — 40,000 $23.01 $951,503
2026-03-04 MITCHELL SHAWNTE Officer — 40,000 $4.37 $174,800
2026-02-02 AUSTIN SASHA LU Officer — 11,700 $0.00 $0
2026-01-20 HARMON CYRUS Director — 10,000 $26.88 $268,800
2026-01-15 KOVACS SHANE WILLIAM CHARLES Chief Operating Officer — 103,822 $28.01 $2,980,054
2026-01-14 HARMON CYRUS Director — 3,489 $29.12 $101,600
2026-01-14 MYLES DAVID C Officer — 110,000 $27.60 $3,107,229
2026-01-14 MYLES DAVID C Officer — 100,000 $4.87 $487,000
2025-12-26 BOHEN SEAN Chief Executive Officer — 8,500 $0.00 $0
2025-12-23 ZOJWALLA NASEEM M.D. Officer — 269,509 $27.66 $7,530,148
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
178.70
+25.62%
142.26
+35.53%
104.96
-1.89%
106.99
Research And Development
157.70
+26.65%
124.52
+44.55%
86.14
+4.70%
82.27
Selling General And Administration
21.00
+18.38%
17.74
-5.74%
18.82
-23.84%
24.71
General And Administrative Expense
21.00
+18.38%
17.74
-5.74%
18.82
-23.84%
24.71
Other Gand A
21.00
+18.38%
17.74
-5.74%
18.82
-23.84%
24.71
Total Expenses
178.70
+25.62%
142.26
+35.53%
104.96
-1.89%
106.99
Operating Income
-178.70
-25.62%
-142.26
-35.53%
-104.96
+1.89%
-106.99
Total Operating Income As Reported
-178.70
-25.62%
-142.26
-35.53%
-104.96
+1.89%
-106.99
EBITDA
-178.21
-25.62%
-141.87
-35.65%
-104.58
+1.92%
-106.63
Normalized EBITDA
-178.21
-25.62%
-141.87
-35.65%
-104.58
+1.92%
-106.63
Reconciled Depreciation
0.49
+24.68%
0.39
+4.24%
0.38
+5.60%
0.36
EBIT
-178.70
-25.62%
-142.26
-35.53%
-104.96
+1.89%
-106.99
Net Income
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Pretax Income
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Net Non Operating Interest Income Expense
16.22
+27.93%
12.68
+52.34%
8.32
+273.65%
2.23
Interest Expense Non Operating
—
—
—
—
Net Interest Income
16.22
+27.93%
12.68
+52.34%
8.32
+273.65%
2.23
Interest Expense
—
—
—
—
Interest Income Non Operating
16.22
+27.93%
12.68
+52.34%
8.32
+273.65%
2.23
Interest Income
16.22
+27.93%
12.68
+52.34%
8.32
+273.65%
2.23
Other Income Expense
0.02
-77.45%
0.10
+636.84%
-0.02
+29.63%
-0.03
Other Non Operating Income Expenses
0.02
-77.45%
0.10
+636.84%
-0.02
+29.63%
-0.03
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Net Income From Continuing Operation Net Minority Interest
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Net Income From Continuing And Discontinued Operation
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Net Income Continuous Operations
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Normalized Income
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Net Income Common Stockholders
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-2.20
-2.80%
-2.14
+18.32%
-2.62
Basic EPS
—
-2.20
-2.80%
-2.14
+18.32%
-2.62
Basic Average Shares
—
58.74
+29.83%
45.25
+13.13%
40.00
Diluted Average Shares
—
58.74
+29.83%
45.25
+13.13%
40.00
Diluted NI Availto Com Stockholders
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Line Item Trend 2023-12-31
Total Assets
276.94
Current Assets
266.51
Cash Cash Equivalents And Short Term Investments
261.81
Cash And Cash Equivalents
68.54
Other Short Term Investments
193.27
Receivables
0.67
Taxes Receivable
—
Accrued Interest Receivable
0.67
Prepaid Assets
2.35
Other Current Assets
1.68
Total Non Current Assets
10.43
Net PPE
3.26
Gross PPE
3.26
Accumulated Depreciation
—
Machinery Furniture Equipment
—
Other Properties
3.26
Non Current Prepaid Assets
7.17
Other Non Current Assets
—
Total Liabilities Net Minority Interest
23.05
Current Liabilities
21.62
Payables And Accrued Expenses
15.17
Payables
2.77
Accounts Payable
2.70
Current Accrued Expenses
12.40
Pensionand Other Post Retirement Benefit Plans Current
5.46
Total Tax Payable
0.07
Current Debt And Capital Lease Obligation
0.99
Current Capital Lease Obligation
0.99
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
1.43
Long Term Debt And Capital Lease Obligation
1.43
Long Term Debt
—
Long Term Capital Lease Obligation
1.43
Stockholders Equity
253.90
Common Stock Equity
253.90
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
55.10
Ordinary Shares Number
54.99
Treasury Shares Number
0.10
Additional Paid In Capital
559.18
Retained Earnings
-305.63
Gains Losses Not Affecting Retained Earnings
0.35
Other Equity Adjustments
0.35
Total Equity Gross Minority Interest
253.90
Total Capitalization
253.90
Working Capital
244.89
Invested Capital
253.90
Total Debt
2.42
Capital Lease Obligations
2.42
Net Tangible Assets
253.90
Tangible Book Value
253.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-146.72
-40.60%
-104.35
-24.63%
-83.73
-2.03%
-82.06
Cash Flow From Continuing Operating Activities
-146.72
-40.60%
-104.35
-24.63%
-83.73
-2.03%
-82.06
Net Income From Continuing Operations
-162.45
-25.47%
-129.47
-33.95%
-96.66
+7.76%
-104.79
Depreciation Amortization Depletion
0.49
+24.68%
0.39
+4.24%
0.38
+5.60%
0.36
Depreciation And Amortization
0.49
+24.68%
0.39
+4.24%
0.38
+5.60%
0.36
Other Non Cash Items
-5.12
+27.17%
-7.03
-66.19%
-4.23
-922.37%
0.51
Stock Based Compensation
17.59
-22.12%
22.58
+30.86%
17.26
-8.35%
18.83
Operating Gains Losses
—
0.01
-91.89%
0.11
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
-91.89%
0.11
0.00
Change In Working Capital
2.77
-69.72%
9.16
+1655.86%
-0.59
-119.49%
3.02
Change In Prepaid Assets
-5.42
-1162.94%
-0.43
-161.82%
0.69
+135.43%
-1.96
Change In Payables And Accrued Expense
4.60
+83.19%
2.51
+8.00%
2.32
+562.11%
0.35
Change In Payable
4.60
+83.19%
2.51
+8.00%
2.32
+562.11%
0.35
Change In Account Payable
4.60
+83.19%
2.51
+8.00%
2.32
+562.11%
0.35
Change In Other Current Assets
-6.14
-107.81%
-2.96
+44.46%
-5.32
-377.92%
-1.11
Change In Other Current Liabilities
9.74
-2.99%
10.04
+484.74%
1.72
-70.11%
5.74
Investing Cash Flow
-155.76
-66.54%
-93.53
-1827.97%
-4.85
-105.30%
91.48
Cash Flow From Continuing Investing Activities
-155.76
-66.54%
-93.53
-1827.97%
-4.85
-105.30%
91.48
Net PPE Purchase And Sale
0.00
+100.00%
-0.16
-1235.71%
0.01
+103.86%
-0.36
Purchase Of PPE
0.00
+100.00%
-0.16
0.00
+100.00%
-0.36
Sale Of PPE
—
0.00
-100.00%
0.01
0.00
Capital Expenditure
—
-0.16
—
-0.36
Net Investment Purchase And Sale
-155.76
-66.83%
-93.37
-1819.16%
-4.87
-105.30%
91.84
Purchase Of Investment
-500.72
-26.78%
-394.96
-54.51%
-255.62
-19.64%
-213.66
Sale Of Investment
344.96
+14.38%
301.59
+20.27%
250.76
-17.92%
305.50
Financing Cash Flow
211.30
-21.40%
268.82
+101.49%
133.41
+27928.36%
0.48
Cash Flow From Continuing Financing Activities
211.30
-21.40%
268.82
+101.49%
133.41
+27928.36%
0.48
Net Issuance Payments Of Debt
3.00
0.00
—
—
Issuance Of Debt
3.00
0.00
—
—
Long Term Debt Issuance
3.00
0.00
—
—
Net Long Term Debt Issuance
3.00
0.00
—
—
Net Common Stock Issuance
205.39
-22.87%
266.29
+105.25%
129.74
0.00
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
9.42
+272.37%
2.53
-31.23%
3.68
+672.90%
0.48
Net Other Financing Charges
-6.51
—
—
—
Changes In Cash
-91.18
-228.53%
70.94
+58.22%
44.84
+353.36%
9.89
Beginning Cash Position
139.48
+103.50%
68.54
+189.17%
23.70
+71.60%
13.81
End Cash Position
48.30
-65.37%
139.48
+103.50%
68.54
+189.17%
23.70
Free Cash Flow
-146.72
-40.38%
-104.51
-24.82%
-83.73
-1.58%
-82.43
Amortization Of Securities
—
—
—
-0.79
Common Stock Issuance
205.39
-22.87%
266.29
+105.25%
129.74
0.00
Issuance Of Capital Stock
205.39
-22.87%
266.29
+105.25%
129.74
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Preferred Stock Payments
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category